Baseline and procedure characteristics of patients with MeVO and LVO
| Baseline and procedure variables | All patients (n=1032) | MeVO (n=147) | LVO (n=885) | P value |
| Age, year, median (IQR） | 66 (56–74) | 67 (59–75) | 66 (56–73) | 0.120 |
| Men, n (%) | 620 (60.1) | 75 (51.0) | 545 (61.6) | 0.016 |
| Hypertension, n (%) | 551 (53.4) | 81 (55.1) | 470 (53.1) | 0.654 |
| DM, n (%) | 177 (17.2) | 23 (15.7) | 154 (17.4) | 0.601 |
| Hyperlipidaemia, n (%) | 80 (7.8) | 6 (4.1) | 74 (8.4) | 0.072 |
| Coronary heart disease, n (%) | 149 (14.4) | 20 (13.6) | 129 (14.6) | 0.757 |
| Atrial fibrillation, n (%) | 408 (39.5) | 59 (40.1) | 349 (39.4) | 0.872 |
| Valvular heart disease, n(%) | 82 (8.0) | 6 (4.1) | 76 (8.6) | 0.061 |
| Prior stroke, n (%) | 222 (21.5) | 36 (24.5) | 186 (21.0) | 0.343 |
| Smoking history, n (%) | 0.357 | |||
| Never smoking | 665 (64.4) | 100 (68.0) | 565 (63.8) | |
| Previous smoking | 65(6.3) | 11(7.5) | 54(6.1) | |
| Current smoking | 302(29.3) | 36(24.5) | 266(30.1) | |
| SBP, mm Hg | 145 (130–160) | 145 (132–160) | 144 (130–160) | 0.725 |
| Baseline NIHSS* | 15 (12–20) | 16 (11–19) | 15 (12–20) | 0.673 |
| ASPECTS† | 9 (7–10) | 10 (8–10) | 9 (7–10) | 0.005 |
| Serum glucose, mmol/L, median (IQR) | 6.8 (5.9–8.5) | 6.7 (5.8–7.9) | 6.8 (5.9–8.6) | 0.440 |
| Blood WBC, 109/L, median (IQR) | 8.2 (6.7–10.2) | 8.1 (6.6–10.6) | 8.3 (6.8–10.2) | 0.816 |
| NLR, median (IQR） | 4.2 (2.5–6.9） | 4.0 (2.5–7.0) | 4.2 (2.5–6.8) | 0.788 |
| Pretreatment with antiplatelets, n (%) | 163(15.8) | 24(16.3) | 139(15.7) | 0.849 |
| Pretreatment with IVT, n (%) | 302 (29.3) | 44 (29.9) | 258 (29.2) | 0.848 |
| Underlying ICAD, n (%) | 0.068 | |||
| Yes | 261 (25.3) | 26 (17.7) | 235 (26.6) | |
| No | 670 (64.9) | 566 (64.0) | 104 (70.8) | |
| Undetermined | 101 (9.8) | 17 (11.6) | 84 (9.5) | |
| General anaesthesia, n (%) | 336 (32.6) | 44 (29.9) | 292 (33.0) | 0.463 |
| Stroke subtype by TOAST criteria | 0.089 | |||
| Large artery atherosclerosis | 429 (41.6) | 55 (37.4) | 374 (42.3) | |
| Cardioembolism | 447 (43.3) | 62 (42.2) | 385 (43.5) | |
| Other or unknown aetiology | 108 (10.5) | 24 (16.3) | 84 (9.5) | |
| Undetermined | 48 (4.7) | 6 (4.1) | 42 (4.8) | |
| Stent retriever, n (%) | 940 (91.1) | 133 (90.5) | 807 (91.2) | 0.780 |
| Aspiration, n (%) | 217 (21.0) | 15 (10.2) | 202 (22.8) | 0.001 |
| IAT, n (%) | 76 (7.4) | 21 (14.3) | 55 (6.2) | 0.001 |
| Balloon angioplasty, n (%) | 143 (13.9) | 9 (6.1) | 134 (15.1) | 0.003 |
| Stenting, n (%) | 113 (11.0) | 5 (3.4) | 108 (12.2) | 0.002 |
| GP IIb/IIIa receptor inhibitor during EVT, n (%) | 485 (47.0) | 53 (36.1) | 432 (48.8) | 0.004 |
| OTP, min, median (IQR)‡ | 300 (212–440) | 286 (205–410) | 300 (215–450) | 0.168 |
| Number of MT passes, median (IQR) | 2 (1–3) | 1 (1–2) | 2 (1–3) | 0.001 |
| FPR, n (%) | 514 (49.9) | 84 (57.5) | 430 (48.6) | 0.047 |
| Procedure duration, min, median (IQR)§ | 80 (50–120) | 74 (45–105) | 80 (50–125) | 0.038 |
| Intraprocedural embolisation, n (%) | 59 (5.7) | 6 (4.1) | 53 (6.0) | 0.356 |
Bold values indicate statistical significance.
*Four missing data.
†Five missing data.
‡ Thirteen missing data.
§ One missing data.
ASPECTS, Alberta Stroke Programme Early CT Score; DM, diabetes mellitus; EVT, endovascular treatment; FPR, first pass recanalisation; IAT, intra-arterial thrombolysis; ICAD, Intracranial atherosclerotic disease; IVT, intravenous thrombolysis; LVO, large vessel occlusion; MeVO, medium vessel occlusion; MT, mechanical thrombectomy; NIHSS, National Institute of Health Stroke Scale; NLR, neutrophil to lymphocyte ratio; OTP, Onset-to-puncture time; SBP, systolic blood pressure; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; WBC, white cell count.